The US Food and Drug Administration (FDA) says shortages of popular diabetes medications Ozempic and Wegovy have ended, with Novo Nordisk able to meet current demand. However, some supply disruptions may occur as the drugs are distributed from manufacturers to pharmacies. Compounding pharmacies will need to wind down production in a few months. The shortage started in 2022 and affected Eli Lilly’s Zepbound and Mounjaro, which use the same active ingredient as Ozempic and Wegovy. GLP-1 class treatments have shown promising results for weight loss, but soaring sales have been hindered by shortages and insurance issues.
Source: https://apnews.com/article/wegovy-ozempic-obesity-diabetes-treatment-shortage-a5f94b1dd7449e15a17922f5503354d6